NOVOCURE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.78 USD | +4.16% |
|
+16.98% | -1.00% |
| May. 02 | NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue | MT |
| May. 02 | BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg | MT |
Chart calendar NovoCure Limited
8f93e17.Bh0JRQPyYzxzIh6BmRLsiJZFNND3h7gmPTv1s35Em-0.SytqdmXLVGgRUSjL8UO7zM8ccIqe3ottXE6Q3Ags9Nl-d1tyUrUuZgR2fQ~974db7981f05a63b2e72f99be89f2b53
Upcoming events on NovoCure Limited
Past events on NovoCure Limited
| 2024-05-02 08:00 am | Q1 2024 Earnings Call |
| 2024-05-02 07:00 am | Q1 2024 Earnings Release |
| 2024-03-27 08:00 am | METIS Phase 3 Results Call |
| 2024-02-22 08:00 am | Q4 2023 Earnings Call |
| 2024-02-22 07:00 am | Q4 2023 Earnings Release |
| 2024-01-10 10:30 am | JPMorgan Healthcare Conference |
| 2023-11-29 03:30 pm | Piper Sandler Healthcare Conference - Fireside Chat |
| 2023-11-18 11:35 am | Society for Neuro Oncology Meeting |
| 2023-11-17 11:06 pm | Society for Neuro Oncology Meeting |
| 2023-11-17 10:30 pm | Society for Neuro Oncology Meeting - Prolonged |
| 2023-11-17 10:30 pm | Society for Neuro Oncology Meeting |
| 2023-11-17 10:30 pm | Society for Neuro Oncology Meeting - Molecular characterization |
| 2023-11-17 10:30 pm | Society for Neuro Oncology Meeting - Development of Tumor |
| 2023-11-17 10:30 pm | Society for Neuro Oncology Meeting - Tumor Treating Fields |
| 2023-11-17 10:30 pm | Society for Neuro Oncology Meeting - Adopting Tumor |
| 2023-11-17 10:30 pm | Society for Neuro Oncology Meeting - The pivotal TRIDENT |
| 2023-11-17 10:30 pm | Society for Neuro Oncology Meeting - The pivotal METIS |
| 2023-11-17 10:30 pm | Society for Neuro Oncology Meeting - Investigating safety |
| 2023-11-17 10:30 pm | Society for Neuro Oncology Meeting - Advanced MRI |
| 2023-11-17 10:30 pm | Society for Neuro Oncology Meeting - Distant progression |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 351 351 0.05% | 494 494 0.14% | 535 539 -0.81% | 538 537 0.15% | 509 509 -0.01% | 550 |
|
EBITDA Million USD | Released Forecast Spread | 7,55 9,20 -17.93% | 39,6 40,3 -1.87% | -34,1 -20,6 -65.7% | -78,9 -43,7 -80.45% | -222 -233 4.77% | -191 |
|
EBIT Million USD | Released Forecast Spread | -0,91 6,79 -113.45% | 30,4 34,9 -12.99% | -44,3 -28,8 -53.83% | -89,5 -77,0 -16.3% | -233 -246 5.21% | -193 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -8,82 -2,12 -316.03% | 18,1 25,8 -29.93% | -52,1 -36,7 -41.76% | -81,8 -79,7 -2.67% | -192 -208 7.72% | -157 |
|
Net income Million USD | Released Forecast Spread | -7,23 -10,5 31.43% | 19,8 28,8 -31.23% | -58,4 -41,1 -41.81% | -92,5 -88,0 -5.13% | -207 -217 4.38% | -174 |
|
EPS USD | Released Forecast Spread | -0,07 -0,10 31.95% | 0,20 0,26 -23.66% | -0,56 -0,41 -37.32% | -0,88 -0,82 -6.68% | -1,95 -2,02 3.64% | -1,60 |
| Announcement Date | 27/02/20 | 25/02/21 | 24/02/22 | 23/02/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 138 134 2.42% | 141 135 4.25% | 131 133 -1.79% | 128 127 0.75% | 122 128 -4.49% | 126 124 1.45% | 127 129 -1.12% | 134 134 -0.01% | 139 131 5.37% | 135 | 137 | 140 | 146 | 146 |
|
EBITDA Million USD | Released Forecast Spread | 1,80 -20,3 108.87% | -18,5 -11,6 -59.56% | -22,0 -23,8 7.88% | -40,3 -24,4 -64.79% | -57,5 -36,2 -58.72% | -59,9 -54,6 -9.7% | -55,4 -60,5 8.34% | -49,0 -59,1 17.12% | -38,7 -59,0 34.35% | -51,6 | -52,0 | -50,4 | -42,9 | -53,9 |
|
EBIT Million USD | Released Forecast Spread | -0,81 -18,4 95.63% | -21,1 -12,9 -63.63% | -24,6 -25,8 4.65% | -43,0 -29,1 -47.83% | -60,2 -35,5 -69.72% | -62,7 -60,2 -4.15% | -58,2 -65,5 11.12% | -51,7 -64,6 19.94% | -41,5 -53,8 22.83% | -49,8 | -50,5 | -51,4 | -45,9 | -57,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -2,52 -22,1 88.63% | -23,4 -15,7 -48.36% | -23,4 -28,9 18.94% | -32,6 -30,5 -6.76% | -51,1 -35,5 -43.89% | -53,9 -51,0 -5.71% | -48,2 -56,8 15.1% | -38,5 -54,7 29.49% | -31,6 -41,4 23.66% | -42,0 | -43,5 | -45,8 | -39,5 | -50,6 |
|
Net income Million USD | Released Forecast Spread | -4,65 -19,9 76.69% | -24,0 -15,6 -53.44% | -26,6 -28,9 7.94% | -37,3 -32,8 -13.79% | -53,1 -37,9 -40.18% | -57,4 -52,2 -9.94% | -49,5 -56,0 11.65% | -47,1 -56,6 16.75% | -38,8 -45,1 14.15% | -44,5 | -45,1 | -46,1 | -39,5 | -50,6 |
|
EPS USD | Released Forecast Spread | -0,04 -0,19 79.32% | -0,23 -0,14 -59.3% | -0,25 -0,28 9.18% | -0,36 -0,31 -15.31% | -0,50 -0,34 -47.06% | -0,54 -0,50 -8% | -0,46 -0,53 12.38% | -0,45 -0,52 13.7% | -0,36 -0,42 14.24% | -0,41 | -0,42 | -0,44 | -0,38 | -0,43 |
| Announcement Date | 28/04/22 | 28/07/22 | 27/10/22 | 23/02/23 | 04/05/23 | 27/07/23 | 26/10/23 | 22/02/24 | 02/05/24 | - | - | - | - | - |
| Today 04:09 pm | SI-BONE, INC.: Q1 2024 Earnings Release |
| 2024-05-07 04:05 pm | MASIMO CORPORATION: Q1 2024 Earnings Release |
| 2024-05-07 04:05 pm | TREACE MEDICAL CONCEPTS, INC.: Q1 2024 Earnings Release |
| 2024-05-07 04:05 pm | PENUMBRA, INC.: Q1 2024 Earnings Release |
| 2024-05-07 | CHEMOMETEC A/S: Q3 2024 Earnings Release |
| 2024-05-08 | WON TECH CO.,LTD.: Q1 2024 Earnings Release (Projected) |
| 2024-05-14 | ASAHI INTECC CO., LTD.: Q3 2024 Earnings Release |
| 2024-05-14 | IMPLANTICA AG: Q1 2024 Earnings Release |
| 2024-07-18 02:00 am | GETINGE AB: Q2 2024 Earnings Release |
| 2024-07-23 | CVRX, INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for NovoCure Limited
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- NVCR Stock
- Calendar NovoCure Limited